Vinod K. Rustgi

19.6k total citations · 5 hit papers
173 papers, 13.8k citations indexed

About

Vinod K. Rustgi is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Vinod K. Rustgi has authored 173 papers receiving a total of 13.8k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Hepatology, 108 papers in Epidemiology and 32 papers in Surgery. Recurrent topics in Vinod K. Rustgi's work include Liver Disease Diagnosis and Treatment (89 papers), Hepatitis C virus research (71 papers) and Liver Disease and Transplantation (47 papers). Vinod K. Rustgi is often cited by papers focused on Liver Disease Diagnosis and Treatment (89 papers), Hepatitis C virus research (71 papers) and Liver Disease and Transplantation (47 papers). Vinod K. Rustgi collaborates with scholars based in United States, Germany and France. Vinod K. Rustgi's co-authors include Stuart C. Gordon, Mitchell L. Shiffman, Janice K. Albrecht, John G. McHutchison, Zachary Goodman, Robert Reindollar, Kenneth Koury, Michael P. Manns, William M. Lee and Eugene R. Schiff and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Vinod K. Rustgi

165 papers receiving 13.3k citations

Hit Papers

Peginterferon alfa-2b plus ribavirin compared with int... 1986 2026 1999 2012 2001 1998 1998 1986 2012 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    2001 4.8k citations John G. McHutchison, Stuart C. Gordon et al. profile →
  2. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
    1998 2.8k citations John G. McHutchison, Stuart C. Gordon et al. New England Journal of Medicine profile →
  3. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C
    1998 1.1k citations Gary L. Davis, Rafael Esteban et al. New England Journal of Medicine profile →
  4. Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha Interferon
    1986 740 citations Vinod K. Rustgi et al. New England Journal of Medicine profile →
  5. Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
    2012 454 citations Vinod K. Rustgi et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vinod K. Rustgi United States 35 11.9k 10.7k 1.6k 1.2k 782 173 13.8k
M. Diago Spain 34 10.7k 0.9× 10.8k 1.0× 990 0.6× 976 0.8× 683 0.9× 131 12.8k
Xavier Forns Spain 61 12.7k 1.1× 11.8k 1.1× 1.4k 0.9× 821 0.7× 591 0.8× 325 15.0k
Karen L. Lindsay United States 52 9.5k 0.8× 9.0k 0.8× 793 0.5× 1.1k 0.9× 831 1.1× 150 12.9k
Tarik Asselah France 58 9.3k 0.8× 9.3k 0.9× 1.3k 0.8× 684 0.6× 1.1k 1.4× 290 12.0k
Ira M. Jacobson United States 64 17.0k 1.4× 15.7k 1.5× 3.0k 1.9× 1.5k 1.3× 1.0k 1.3× 338 19.9k
Andrew J. Muir United States 41 8.1k 0.7× 7.3k 0.7× 1.0k 0.6× 1.4k 1.1× 781 1.0× 213 11.2k
Yasuji Arase Japan 52 9.1k 0.8× 8.7k 0.8× 873 0.5× 714 0.6× 878 1.1× 394 11.6k
Wan‐Long Chuang Taiwan 53 8.5k 0.7× 8.3k 0.8× 733 0.5× 616 0.5× 939 1.2× 513 11.1k
Paul J. Pockros United States 50 6.5k 0.5× 6.2k 0.6× 1.1k 0.7× 650 0.5× 493 0.6× 190 8.5k
Ming‐Lung Yu Taiwan 53 7.4k 0.6× 7.7k 0.7× 707 0.4× 614 0.5× 1.1k 1.5× 490 10.8k

Countries citing papers authored by Vinod K. Rustgi

Since Specialization
Citations

This map shows the geographic impact of Vinod K. Rustgi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vinod K. Rustgi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vinod K. Rustgi more than expected).

Fields of papers citing papers by Vinod K. Rustgi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vinod K. Rustgi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vinod K. Rustgi. The network helps show where Vinod K. Rustgi may publish in the future.

Co-authorship network of co-authors of Vinod K. Rustgi

This figure shows the co-authorship network connecting the top 25 collaborators of Vinod K. Rustgi. A scholar is included among the top collaborators of Vinod K. Rustgi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vinod K. Rustgi. Vinod K. Rustgi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elsaid, Mohamed I., et al.. (2024). The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease. PLoS ONE. 19(3). e0299836–e0299836. 8 indexed citations
2.
Gupta, Kapil, Haroon Shahid, Amy Tyberg, et al.. (2024). OVERVIEWING THE SAFETY AND EFFICACY OF ENDOSCOPIC ULTRASOUND (EUS) GUIDED PORTAL PRESSURE GRADIENT (PPG) WITH SIMULTANEOUS LIVER BIOPSY. Gastrointestinal Endoscopy. 99(6). AB851–AB851.
3.
Tait, Christopher, et al.. (2023). Early-Onset Colorectal Cancer: Prevalence, Risk Factors, and Clinical Features Among Commercially Insured Adults in the United States. Cureus. 15(11). e49432–e49432. 1 indexed citations
4.
5.
Chen, Alexander, et al.. (2023). Demographics and Outcomes Related to Wilson’s Disease Patients: A Nationwide Inpatient Cohort Study. Cureus. 15(9). e44714–e44714. 2 indexed citations
6.
Rattan, Puru, Carlos D. Minacapelli, & Vinod K. Rustgi. (2020). The Microbiome and Hepatocellular Carcinoma. Liver Transplantation. 26(10). 1316–1327. 25 indexed citations
7.
Flamm, Steven L., Edward Gane, Jean‐François Dufour, et al.. (2014). Safety of ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients >= 65 Years of Age: Results From Phase 2 and 3 Trials. Hepatology. 60. 4 indexed citations
8.
Fung, Scott, Stuart C. Gordon, Zahary Krastev, et al.. (2014). Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). Liver International. 35(2). 422–428. 4 indexed citations
9.
Nelson, David R., Stefan Zeuzem, Pietro Andreoné, et al.. (2012). Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients( ). Annals of Hepatology. 11(1). 15–31. 41 indexed citations
10.
Läwitz, E., Vinod K. Rustgi, Tarek Hassanein, et al.. (2010). 2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS. Journal of Hepatology. 52. S467–S467. 34 indexed citations
11.
Rustgi, Vinod K., et al.. (2010). Update on Chronic Hepatitis B. The Journal for Nurse Practitioners. 6(8). 631–639. 1 indexed citations
12.
Zeuzem, Stefan, Mark Sulkowski, E. Läwitz, et al.. (2009). 1041 EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT- NAIVE, CHRONIC HEPATITIS C GENOTYPE 1 (CHC G1) PATIENTS. Journal of Hepatology. 50. S377–S377. 13 indexed citations
13.
Rustgi, Vinod K.. (2005). Thymalfasin for the treatment of chronic hepatitis C infection. Expert Review of Anti-infective Therapy. 3(6). 885–892. 10 indexed citations
14.
15.
Rustgi, Vinod K., Sheila D. Rustgi, Michael T. Halpern, et al.. (2004). Impact of body mass index on graft failure and overall survival following liver transplant*. Clinical Transplantation. 18(6). 634–637. 29 indexed citations
16.
Marroquin, Carlos E., Paul C. Kuo, Jeffrey S. Plotkin, et al.. (2001). Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transplantation. 7(9). 762–768. 73 indexed citations
17.
Kuo, Paul C., Jeffrey S. Plotkin, Seán Gaine, et al.. (1999). PORTOPULMONARY HYPERTENSION AND THE LIVER TRANSPLANT CANDIDATE. Transplantation. 67(8). 1087–1093. 103 indexed citations
18.
Davis, Gary L., Rafael Esteban, Vinod K. Rustgi, et al.. (1998). Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. New England Journal of Medicine. 339(21). 1493–1499. 1070 indexed citations breakdown →
19.
20.
Rustgi, Vinod K., et al.. (1984). Psychiatric manifestations of inflammatory bowel disease. Critical review and future strategies.. PubMed. 2(4). 337–49. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Diago Breakdown of academic impact, for papers by Xavier Forns Breakdown of academic impact, for papers by Karen L. Lindsay Breakdown of academic impact, for papers by Tarik Asselah Breakdown of academic impact, for papers by Ira M. Jacobson Breakdown of academic impact, for papers by Andrew J. Muir Breakdown of academic impact, for papers by Yasuji Arase Breakdown of academic impact, for papers by Wan‐Long Chuang Breakdown of academic impact, for papers by Paul J. Pockros Breakdown of academic impact, for papers by Ming‐Lung Yu
Rankless by CCL
2026